The Effectiveness of the Combined Use of Meropenem and Avibactam Against Carbapenemase-Producing <i>Klebsiella pneumoniae</i> Strains in an <i>in vitro</i> Dynamic Model

Background. Combinations of carbapenems with new-generation carbapenemase inhibitors are successfully used to combat infections caused by carbapenemase-producing Klebsiella pneumoniae strains. However, K. pneumoniae resistance to such combinations is already described. Therefore, the search for new...

Full description

Saved in:
Bibliographic Details
Main Authors: E. N. Strukova, M. V. Golikova, M. B. Kobrin, S. A. Dovzhenko, A. V. Golyshkin, N. R. Almyasheva, Yu. A. Portnoy
Format: Article
Language:Russian
Published: LLC "Publishing House OKI" 2025-04-01
Series:Антибиотики и Химиотерапия
Subjects:
Online Access:https://www.antibiotics-chemotherapy.ru/jour/article/view/1203
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849692982072049664
author E. N. Strukova
M. V. Golikova
M. B. Kobrin
S. A. Dovzhenko
A. V. Golyshkin
N. R. Almyasheva
Yu. A. Portnoy
author_facet E. N. Strukova
M. V. Golikova
M. B. Kobrin
S. A. Dovzhenko
A. V. Golyshkin
N. R. Almyasheva
Yu. A. Portnoy
author_sort E. N. Strukova
collection DOAJ
description Background. Combinations of carbapenems with new-generation carbapenemase inhibitors are successfully used to combat infections caused by carbapenemase-producing Klebsiella pneumoniae strains. However, K. pneumoniae resistance to such combinations is already described. Therefore, the search for new antibiotic/inhibitor combinations is important. In this regard, meropenem/avibactam combination seems promising, with its effectiveness becoming the subject of the current study.The aim of this study was to evaluate the effectiveness of the combination of meropenem with the new carbapenemase inhibitor avibactam against carbapenemase-producing K. pneumoniae strains in an in vitro dynamic model.Methods. Two carbapenemase-producing strains, KPC (K. pneumoniae 28) and OXA-48 (K. pneumoniae 145), were exposed to meropenem or its combination with avibactam in the hollow fiber infection model that simulated the pharmacokinetic profiles of drugs in the human lung epithelial fluid. The following dosage regimens were simulated: 2000 mg of meropenem and 500 mg of avibactam as a 2-hour infusion every 8 hours during 5 days. The effect of the drugs on the total and resistant subpopulations of K. pneumoniae was evaluated by plating samples on agar media without and with meropenem at different MIC-fold concentrations.Results. Meropenem alone did not reduce the numbers of the total population and did not suppress the growth of resistant subpopulations of both strains, while combining meropenem with avibactam significantly reduced the total bacterial numbers and completely prevented the growth of resistant cells.Conclusion. The combination of meropenem/avibactam seems promising, due to the fact that it was characterized by high efficacy and a lack of development of resistance to meropenem throughout the entire simulated course of therapy.
format Article
id doaj-art-3b2aa3025ae948e1ac743c8d85c3459e
institution DOAJ
issn 0235-2990
language Russian
publishDate 2025-04-01
publisher LLC "Publishing House OKI"
record_format Article
series Антибиотики и Химиотерапия
spelling doaj-art-3b2aa3025ae948e1ac743c8d85c3459e2025-08-20T03:20:33ZrusLLC "Publishing House OKI"Антибиотики и Химиотерапия0235-29902025-04-016911-12324010.37489/0235-2990-2024-69-11-12-32-401073The Effectiveness of the Combined Use of Meropenem and Avibactam Against Carbapenemase-Producing <i>Klebsiella pneumoniae</i> Strains in an <i>in vitro</i> Dynamic ModelE. N. Strukova0M. V. Golikova1M. B. Kobrin2S. A. Dovzhenko3A. V. Golyshkin4N. R. Almyasheva5Yu. A. Portnoy6Gause Institute of New Antibiotics (GINA)Gause Institute of New Antibiotics (GINA)Gause Institute of New Antibiotics (GINA)Gause Institute of New Antibiotics (GINA)Gause Institute of New Antibiotics (GINA)Gause Institute of New Antibiotics (GINA)Gause Institute of New Antibiotics (GINA)Background. Combinations of carbapenems with new-generation carbapenemase inhibitors are successfully used to combat infections caused by carbapenemase-producing Klebsiella pneumoniae strains. However, K. pneumoniae resistance to such combinations is already described. Therefore, the search for new antibiotic/inhibitor combinations is important. In this regard, meropenem/avibactam combination seems promising, with its effectiveness becoming the subject of the current study.The aim of this study was to evaluate the effectiveness of the combination of meropenem with the new carbapenemase inhibitor avibactam against carbapenemase-producing K. pneumoniae strains in an in vitro dynamic model.Methods. Two carbapenemase-producing strains, KPC (K. pneumoniae 28) and OXA-48 (K. pneumoniae 145), were exposed to meropenem or its combination with avibactam in the hollow fiber infection model that simulated the pharmacokinetic profiles of drugs in the human lung epithelial fluid. The following dosage regimens were simulated: 2000 mg of meropenem and 500 mg of avibactam as a 2-hour infusion every 8 hours during 5 days. The effect of the drugs on the total and resistant subpopulations of K. pneumoniae was evaluated by plating samples on agar media without and with meropenem at different MIC-fold concentrations.Results. Meropenem alone did not reduce the numbers of the total population and did not suppress the growth of resistant subpopulations of both strains, while combining meropenem with avibactam significantly reduced the total bacterial numbers and completely prevented the growth of resistant cells.Conclusion. The combination of meropenem/avibactam seems promising, due to the fact that it was characterized by high efficacy and a lack of development of resistance to meropenem throughout the entire simulated course of therapy.https://www.antibiotics-chemotherapy.ru/jour/article/view/1203meropenem, avibactamk. pneumoniaehollow fiber infection model, pharmacokinetics, pharmacodynamics
spellingShingle E. N. Strukova
M. V. Golikova
M. B. Kobrin
S. A. Dovzhenko
A. V. Golyshkin
N. R. Almyasheva
Yu. A. Portnoy
The Effectiveness of the Combined Use of Meropenem and Avibactam Against Carbapenemase-Producing <i>Klebsiella pneumoniae</i> Strains in an <i>in vitro</i> Dynamic Model
Антибиотики и Химиотерапия
meropenem, avibactam
k. pneumoniae
hollow fiber infection model, pharmacokinetics, pharmacodynamics
title The Effectiveness of the Combined Use of Meropenem and Avibactam Against Carbapenemase-Producing <i>Klebsiella pneumoniae</i> Strains in an <i>in vitro</i> Dynamic Model
title_full The Effectiveness of the Combined Use of Meropenem and Avibactam Against Carbapenemase-Producing <i>Klebsiella pneumoniae</i> Strains in an <i>in vitro</i> Dynamic Model
title_fullStr The Effectiveness of the Combined Use of Meropenem and Avibactam Against Carbapenemase-Producing <i>Klebsiella pneumoniae</i> Strains in an <i>in vitro</i> Dynamic Model
title_full_unstemmed The Effectiveness of the Combined Use of Meropenem and Avibactam Against Carbapenemase-Producing <i>Klebsiella pneumoniae</i> Strains in an <i>in vitro</i> Dynamic Model
title_short The Effectiveness of the Combined Use of Meropenem and Avibactam Against Carbapenemase-Producing <i>Klebsiella pneumoniae</i> Strains in an <i>in vitro</i> Dynamic Model
title_sort effectiveness of the combined use of meropenem and avibactam against carbapenemase producing i klebsiella pneumoniae i strains in an i in vitro i dynamic model
topic meropenem, avibactam
k. pneumoniae
hollow fiber infection model, pharmacokinetics, pharmacodynamics
url https://www.antibiotics-chemotherapy.ru/jour/article/view/1203
work_keys_str_mv AT enstrukova theeffectivenessofthecombineduseofmeropenemandavibactamagainstcarbapenemaseproducingiklebsiellapneumoniaeistrainsinaniinvitroidynamicmodel
AT mvgolikova theeffectivenessofthecombineduseofmeropenemandavibactamagainstcarbapenemaseproducingiklebsiellapneumoniaeistrainsinaniinvitroidynamicmodel
AT mbkobrin theeffectivenessofthecombineduseofmeropenemandavibactamagainstcarbapenemaseproducingiklebsiellapneumoniaeistrainsinaniinvitroidynamicmodel
AT sadovzhenko theeffectivenessofthecombineduseofmeropenemandavibactamagainstcarbapenemaseproducingiklebsiellapneumoniaeistrainsinaniinvitroidynamicmodel
AT avgolyshkin theeffectivenessofthecombineduseofmeropenemandavibactamagainstcarbapenemaseproducingiklebsiellapneumoniaeistrainsinaniinvitroidynamicmodel
AT nralmyasheva theeffectivenessofthecombineduseofmeropenemandavibactamagainstcarbapenemaseproducingiklebsiellapneumoniaeistrainsinaniinvitroidynamicmodel
AT yuaportnoy theeffectivenessofthecombineduseofmeropenemandavibactamagainstcarbapenemaseproducingiklebsiellapneumoniaeistrainsinaniinvitroidynamicmodel
AT enstrukova effectivenessofthecombineduseofmeropenemandavibactamagainstcarbapenemaseproducingiklebsiellapneumoniaeistrainsinaniinvitroidynamicmodel
AT mvgolikova effectivenessofthecombineduseofmeropenemandavibactamagainstcarbapenemaseproducingiklebsiellapneumoniaeistrainsinaniinvitroidynamicmodel
AT mbkobrin effectivenessofthecombineduseofmeropenemandavibactamagainstcarbapenemaseproducingiklebsiellapneumoniaeistrainsinaniinvitroidynamicmodel
AT sadovzhenko effectivenessofthecombineduseofmeropenemandavibactamagainstcarbapenemaseproducingiklebsiellapneumoniaeistrainsinaniinvitroidynamicmodel
AT avgolyshkin effectivenessofthecombineduseofmeropenemandavibactamagainstcarbapenemaseproducingiklebsiellapneumoniaeistrainsinaniinvitroidynamicmodel
AT nralmyasheva effectivenessofthecombineduseofmeropenemandavibactamagainstcarbapenemaseproducingiklebsiellapneumoniaeistrainsinaniinvitroidynamicmodel
AT yuaportnoy effectivenessofthecombineduseofmeropenemandavibactamagainstcarbapenemaseproducingiklebsiellapneumoniaeistrainsinaniinvitroidynamicmodel